Integration has its challenges and drawbacks, but, if successful, Portugal can act as a gateway to significant opportunities, sources say.

Elinzanetant benefits were assessed in younger and older women with moderate hot flashes.

At Gilead, we’re advancing new ways to help end the HIV epidemic by delivering innovative therapies to those who need them most. In our latest episode of The Centrifuge Sessions, Magdeleine Hung, ...

CHICAGO -- The neurokinin-targeted agent elinzanetant significantly reduced the frequency of hot flashes among women receiving endocrine therapy for hormone receptor (HR)-positive breast cancer or ...

GileadNews: We’re joining with Kite Pharma to announce the presentation of transformative cancer research at this year’s American Society of Clinical Oncology (ASCO) and European Hematology ...

Gilead Sciences missed first-quarter revenue estimates as sales of its COVID-19 and cancer drugs declined. The biopharma's profit got a lift from higher prices and demand for its HIV treatments.

Gilead Sciences releases its first-quarter results after Thursday's closing bell. Here's a look at the details from the report.

Gilead Sciences (NASDAQ: GILD) will release its quarterly earnings report on Thursday, 2025-04-24. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Gilead ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what you need to know.

Aside from Gilead, American depositary shares of GSK fell 2.18% in early trading. The multinational biopharma firm is a majority owner of the HIV-focused company Viiv.